Elliott J, et al. - Researchers compared extended dual antiplatelet therapy (DAPT) (>12 months) to DAPT for 6–12 months after PCI with stenting, via an umbrella review of 16 systematic reviews (SRs) of 8 randomized controlled trials (RCTs) with a focus on death, myocardial infarction (MI), stroke, stent thrombosis, major adverse cardiac and cerebrovascular events, bleeding, and urgent revascularization. Among clinically important subgroups (e.g., elderly patients, those with diabetes, prior MI, acute coronary syndrome), they evaluated the evidence of benefits and harms. They used AMSTAR to evaluate the quality of the included reviews. Most of the included trials scored 7 or more points on the AMSTAR checklist. Findings revealed that the risk of MI and stent thrombosis could be attenuated by extended DAPT, however, it increased major bleeding and death. It remained unclear whether the effects of extended DAPT were consistent across patient subgroups.